The inverse benefit law: How drug marketing undermines patient safety and public health

Howard Brody, Donald W. Light

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Recent highly publicized withdrawals of drugs from the market because of safety concerns raise the question of whether these events are random failures or part of a recurring pattern. The inverse benefit law, inspired by Hart's inverse care law, states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively the drugs are marketed. The law is manifested through 6 basic marketing strategies: reducing thresholds for diagnosing disease, relying on surrogate endpoints, exaggerating safety claims, exaggerating efficacy claims, creating new diseases, and encouraging unapproved uses. The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing. (Am J Public Health.

Original languageEnglish (US)
Pages (from-to)399-404
Number of pages6
JournalAmerican Journal of Public Health
Volume101
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Drug Legislation
Patient Safety
Marketing
Public Health
Product Recalls and Withdrawals
Comparative Effectiveness Research
Pharmaceutical Preparations
Patient Harm
Safety
Biomarkers

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

The inverse benefit law : How drug marketing undermines patient safety and public health. / Brody, Howard; Light, Donald W.

In: American Journal of Public Health, Vol. 101, No. 3, 01.03.2011, p. 399-404.

Research output: Contribution to journalArticle

@article{86abab3ebdf646cf8cf031ffa4e6ce36,
title = "The inverse benefit law: How drug marketing undermines patient safety and public health",
abstract = "Recent highly publicized withdrawals of drugs from the market because of safety concerns raise the question of whether these events are random failures or part of a recurring pattern. The inverse benefit law, inspired by Hart's inverse care law, states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively the drugs are marketed. The law is manifested through 6 basic marketing strategies: reducing thresholds for diagnosing disease, relying on surrogate endpoints, exaggerating safety claims, exaggerating efficacy claims, creating new diseases, and encouraging unapproved uses. The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing. (Am J Public Health.",
author = "Howard Brody and Light, {Donald W.}",
year = "2011",
month = "3",
day = "1",
doi = "10.2105/AJPH.2010.199844",
language = "English (US)",
volume = "101",
pages = "399--404",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "3",

}

TY - JOUR

T1 - The inverse benefit law

T2 - How drug marketing undermines patient safety and public health

AU - Brody, Howard

AU - Light, Donald W.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Recent highly publicized withdrawals of drugs from the market because of safety concerns raise the question of whether these events are random failures or part of a recurring pattern. The inverse benefit law, inspired by Hart's inverse care law, states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively the drugs are marketed. The law is manifested through 6 basic marketing strategies: reducing thresholds for diagnosing disease, relying on surrogate endpoints, exaggerating safety claims, exaggerating efficacy claims, creating new diseases, and encouraging unapproved uses. The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing. (Am J Public Health.

AB - Recent highly publicized withdrawals of drugs from the market because of safety concerns raise the question of whether these events are random failures or part of a recurring pattern. The inverse benefit law, inspired by Hart's inverse care law, states that the ratio of benefits to harms among patients taking new drugs tends to vary inversely with how extensively the drugs are marketed. The law is manifested through 6 basic marketing strategies: reducing thresholds for diagnosing disease, relying on surrogate endpoints, exaggerating safety claims, exaggerating efficacy claims, creating new diseases, and encouraging unapproved uses. The inverse benefit law highlights the need for comparative effectiveness research and other reforms to improve evidence-based prescribing. (Am J Public Health.

UR - http://www.scopus.com/inward/record.url?scp=79951594704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951594704&partnerID=8YFLogxK

U2 - 10.2105/AJPH.2010.199844

DO - 10.2105/AJPH.2010.199844

M3 - Article

C2 - 21233426

AN - SCOPUS:79951594704

VL - 101

SP - 399

EP - 404

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 3

ER -